Cencora, Inc.
NYSE•COR
CEO: Mr. Steven H. Collis
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 1995-04-04
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Contact Information
Market Cap
$68.08B
P/E (TTM)
41.8
32.9
Dividend Yield
0.7%
52W High
$377.54
52W Low
$252.49
52W Range
Rank13Top 2.2%
6.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$85.93B+0.00%
4-Quarter Trend
EPS
$2.88+0.00%
4-Quarter Trend
FCF
-$2.42B+0.00%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Revenue Growth Strong Revenue reached $85.93 B USD for the quarter, marking a solid 5.5% increase over the prior year period.
Gross Profit Surges Gross profit surged to $3.07 B USD, showing a strong 20.1% increase driven by recent acquisitions.
Net Income Improvement Net income attributable to Cencora grew to $559.65 M USD, improving significantly from $488.60 M USD last year.
Operating Cash Usage Down Cash used in operating activities decreased by $0.4 B USD, totaling $2.31 B USD utilized this quarter.
Risk Factors
Opioid Litigation Liability Accrued litigation liability for opioid settlements stands at $4.3 B USD, payable across the next thirteen years.
Asset Impairment Recorded Management recorded a $165.7 M USD goodwill impairment charge related to the U.S. Consulting Services business sale.
Interest Expense Spikes Net interest expense increased substantially by 159.2% due to significant new debt issuance for acquisitions.
Geopolitical Uncertainties Remain Exposure remains high regarding geopolitical uncertainties, macroeconomic shifts, and potential supply chain disruptions globally.
Outlook
OneOncology Acquisition Closed The company finalized the majority acquisition of OneOncology for approximately $4.6 B USD cash in February 2026.
New Segment Reporting A new business reporting structure aligning with growth priorities was implemented starting in the first quarter of fiscal 2026.
Credit Facility Expanded The Multi-Currency Revolving Credit Facility was amended, increasing total commitments available up to $5.5 B USD.
Quarterly Dividend Raised Anticipating continued capital needs, the Board increased the quarterly common stock dividend by 9% to $0.60 USD.
Peer Comparison
Revenue (TTM)
$397.96B
$325.78B
$244.49B
Gross Margin (Latest Quarter)
89.3%
85.0%
78.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MCK | $116.13B | 26.7 | -245.3% | 10.2% |
| REGN | $77.49B | 17.0 | 14.8% | 6.7% |
| COR | $68.08B | 41.8 | 101.4% | 10.1% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.4%
Moderate Growth
4Q Net Income CAGR
-8.0%
Declining Profitability
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data